SCHEMBL26075224

SCHEMBL26075224

COc1ccc(-c2ccc(-c3cc(C)c4cc(Cl)ccc4n3)cc2F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.62
▸ AURKB Q96GD4 1/20 0.62
▸ PLA2G2A P14555 2/20 0.52
▸ KDM4E B2RXH2 2/20 0.48
▸ ACACA Q13085 1/20 0.46
▸ AMY1A P0DUB6 1/20 0.46
▸ ACP1 P24666 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ HPGD P15428 3/20 0.44
▸ DHODH Q02127 5/20 0.43
▸ MAPT P10636 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ PTGES O14684 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075230 0.88 PLA2G2A (0.54) AURKAAURKBPLA2G2AKDM4EACACA
SCHEMBL26075210 0.88 AURKA (0.47) AURKAAURKBPLA2G2AKDM4EACACA
SCHEMBL26075865 0.86 ACACA (0.46) AURKAAURKBPLA2G2AKDM4EACACA
SCHEMBL23590087 0.86 KDM4E (0.69) AURKAAURKBPLA2G2AKDM4EALDH1A1
SCHEMBL26075335 0.84 ACP1 (0.50) AURKAAURKBPLA2G2AKDM4EACACA
SCHEMBL26075308 0.78 DHODH (0.55) PLA2G2AKDM4EACACAALDH1A1HPGD
SCHEMBL26075337 0.78 MAPT (0.49) AURKAAURKBPLA2G2AKDM4EACACA
SCHEMBL26075255 0.76 PLA2G2A (0.41) PLA2G2AKDM4EACP1ALDH1A1HPGD
SCHEMBL26075282 0.76 DHODH (0.43) PLA2G2AACP1DHODH
SCHEMBL23590084 0.76 DHODH (0.67) AURKAAURKBPLA2G2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD AURKA 3217/4885AURKB 2400/4885PLA2G2A 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback